Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.39 +4.8%	$1.96	$1.33 ▼ $3.58	$112.59M	0.74	96,818 shs	193,346 shs
ERAS Erasca	$1.60 +6.7%	$1.48	$1.01 ▼ $3.31	$453.87M	1.07	754,691 shs	1.02 million shs
GOSS Gossamer Bio	$2.34 +7.8%	$1.65	$0.66 ▼ $2.35	$532.07M	1.96	2.92 million shs	4.89 million shs
RGNX REGENXBIO	$9.01 +11.1%	$8.52	$5.03 ▼ $13.48	$455.13M	1.11	680,725 shs	1.36 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	+4.82%	+41.42%	+23.90%	+31.32%	-5.16%
ERAS Erasca	+6.67%	-2.44%	-6.43%	+31.15%	-43.66%
GOSS Gossamer Bio	+7.83%	+19.39%	+25.13%	+95.00%	+148.94%
RGNX REGENXBIO	+11.10%	+2.15%	-0.88%	-7.21%	-26.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAG Adagene	3.0468 of 5 stars	3.5	5.0	0.0	2.6	1.7	0.0
ERAS Erasca	1.9378 of 5 stars	3.4	1.0	0.0	1.0	2.5	0.6
GOSS Gossamer Bio	3.2931 of 5 stars	3.5	1.0	4.7	0.0	1.7	0.0
RGNX REGENXBIO	4.3632 of 5 stars	3.4	3.0	4.6	2.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	3.00	Buy	$7.00	192.89% Upside
ERAS Erasca	2.86	Moderate Buy	$4.29	167.86% Upside
GOSS Gossamer Bio	3.00	Buy	$8.50	263.25% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$28.38	214.93% Upside

Current Analyst Ratings Breakdown

Latest ADAG, GOSS, ERAS, and RGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$34.00
8/18/2025	ERAS Erasca	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00 ➝ $2.00
8/15/2025	ADAG Adagene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
8/8/2025	RGNX REGENXBIO	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $17.00
8/8/2025	RGNX REGENXBIO	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $37.00
8/8/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
8/6/2025	ADAG Adagene	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	ADAG Adagene	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
8/6/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
6/9/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$100K	1,125.93	N/A	N/A	$0.80 per share	2.99
ERAS Erasca	N/A	N/A	N/A	N/A	$1.31 per share	N/A
GOSS Gossamer Bio	$114.70M	4.64	N/A	N/A	($0.20) per share	-11.70
RGNX REGENXBIO	$83.33M	5.46	N/A	N/A	$4.23 per share	2.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$33.42M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	-$161.65M	-$0.45	N/A	N/A	N/A	N/A	-31.19%	-26.34%	11/11/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.62	N/A	N/A	N/A	-344.81%	-1,774.72%	-46.73%	11/6/2025 (Estimated)
RGNX REGENXBIO	-$227.10M	-$3.44	N/A	N/A	N/A	-112.70%	-66.95%	-34.14%	11/5/2025 (Estimated)

Latest ADAG, GOSS, ERAS, and RGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ERAS Erasca	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
8/7/2025	Q2 2025	RGNX REGENXBIO	-$1.13	-$1.38	-$0.25	-$1.38	$40.87 million	$21.36 million
8/5/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	-$0.17	+$0.01	-$0.17	$4.12 million	$11.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	2.29	2.30
ERAS Erasca	N/A	11.03	11.04
GOSS Gossamer Bio	6.70	4.40	4.40
RGNX REGENXBIO	N/A	3.13	3.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
ERAS Erasca	67.78%
GOSS Gossamer Bio	81.23%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
ERAS Erasca	14.40%
GOSS Gossamer Bio	6.70%
RGNX REGENXBIO	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	47.11 million	37.12 million	Not Optionable
ERAS Erasca	120	283.67 million	242.82 million	Optionable
GOSS Gossamer Bio	180	227.38 million	212.15 million	Optionable
RGNX REGENXBIO	370	50.51 million	44.05 million	Optionable

ADAG, GOSS, ERAS, and RGNX Headlines

Recent News About These Companies

Leerink Partnrs Expects Reduced Earnings for REGENXBIO

August 23 at 7:45 AM | marketbeat.com

FY2025 EPS Estimates for REGENXBIO Decreased by Analyst

August 23 at 2:45 AM | americanbankingnews.com

REGENXBIO Inc. (NASDAQ:RGNX) Receives $28.38 Consensus Target Price from Analysts

August 22 at 3:05 AM | americanbankingnews.com

HC Wainwright Reaffirms Buy Rating for REGENXBIO (NASDAQ:RGNX)

August 21 at 8:10 AM | marketbeat.com

Voss Capital LP Has $2.79 Million Position in REGENXBIO Inc. $RGNX

August 21 at 6:52 AM | marketbeat.com

Delay hits Regenxbio BLA review

August 20 at 5:35 PM | thepharmaletter.comT

REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from Analysts

August 20 at 2:54 AM | marketbeat.com

REGENXBIO Inc.: REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

August 19, 2025 | finanznachrichten.de

Regenxbio announces FDA review extension for RGX-121 BLA

August 19, 2025 | msn.com

Regenxbio FDA delay ‘not a needle mover,’ says Leerink

August 19, 2025 | msn.com

Analyst Expectations For Regenxbio's Future

August 19, 2025 | benzinga.com

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

August 18, 2025 | prnewswire.com

XTX Topco Ltd Reduces Stake in REGENXBIO Inc. (NASDAQ:RGNX)

August 13, 2025 | marketbeat.com

Are Options Traders Betting on a Big Move in Regenxbio Stock?

August 12, 2025 | msn.com

REGENXBIO (NASDAQ:RGNX) Shares Pass Below 50-Day Moving Average Following Weak Earnings

August 10, 2025 | marketbeat.com

Royal Bank Of Canada Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $17.00

August 10, 2025 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Downgraded to "Strong Sell" Rating by Wall Street Zen

August 10, 2025 | marketbeat.com

These Analysts Just Made An Incredible Downgrade To Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Forecasts

August 9, 2025 | uk.finance.yahoo.com

Barclays Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $37.00

August 9, 2025 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Given Buy Rating at Chardan Capital

August 9, 2025 | marketbeat.com

Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG, GOSS, ERAS, and RGNX Company Descriptions

Adagene NASDAQ:ADAG

$2.39 +0.11 (+4.82%)

Closing price 08/22/2025 03:57 PM Eastern

Extended Trading

$2.42 +0.02 (+1.05%)

As of 08/22/2025 06:54 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Erasca NASDAQ:ERAS

$1.60 +0.10 (+6.67%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.60 -0.01 (-0.31%)

As of 08/22/2025 07:24 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Gossamer Bio NASDAQ:GOSS

$2.34 +0.17 (+7.83%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.30 -0.04 (-1.71%)

As of 08/22/2025 07:40 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

REGENXBIO NASDAQ:RGNX

$9.01 +0.90 (+11.10%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.02 +0.01 (+0.11%)

As of 08/22/2025 04:46 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time